NovoCure Ltd (NVCR)
Every FINRA and SEC series the site collects for NovoCure Ltd: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.
10.8M
Short interest
settlement 2026-08-31
7.6
Days to cover
+17.6% vs prior
47.6%
Short share of volume
2026-09-17
1,422
Fails to deliver
settlement 2026-08-31
Thu 29 Oct
Next earnings
estimated; last year 2025-10-30
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-17.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 31 August 2026, short interest in NVCR is 10,788,851 shares, up 651,305 shares over the last month. Over the last 48 readings it ranged from 4,640,412 shares (30 May 2025) to 11,884,203 shares (30 June 2026). At the reported average volume of 1.4M shares a day that is 7.6 days to cover, elevated.
Embed this chartkeeps the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/nvcr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-31 | 10,788,851 | +17.6% | 1,414,077 | 7.63 |
| 2026-08-14 | 9,170,033 | -9.5% | 1,096,067 | 8.37 |
| 2026-07-31 | 10,137,546 | -11.5% | 2,072,352 | 4.89 |
| 2026-07-15 | 11,460,044 | -3.6% | 1,530,548 | 7.49 |
| 2026-06-30 | 11,884,203 | +23.1% | 1,924,097 | 6.18 |
| 2026-06-15 | 9,650,837 | +5.4% | 1,615,169 | 5.98 |
| 2026-05-29 | 9,153,119 | +7.2% | 1,323,014 | 6.92 |
| 2026-05-15 | 8,541,120 | +22.6% | 1,993,657 | 4.28 |
| 2026-04-30 | 6,967,267 | -20.0% | 1,710,207 | 4.07 |
| 2026-04-15 | 8,707,784 | -3.8% | 1,056,187 | 8.24 |
| 2026-03-31 | 9,055,343 | +6.3% | 1,280,009 | 7.07 |
| 2026-03-13 | 8,518,264 | -6.7% | 1,410,560 | 6.04 |
| 2026-02-27 | 9,127,904 | +2.6% | 2,568,676 | 3.55 |
| 2026-02-13 | 8,899,112 | +11.7% | 3,671,454 | 2.42 |
| 2026-01-30 | 7,970,704 | +7.2% | 1,036,048 | 7.69 |
| 2026-01-15 | 7,432,511 | -10.8% | 1,330,310 | 5.59 |
| 2025-12-31 | 8,333,839 | +20.0% | 1,066,364 | 7.82 |
| 2025-12-15 | 6,943,501 | +1.7% | 2,261,775 | 3.07 |
| 2025-11-28 | 6,827,285 | +14.3% | 1,460,342 | 4.68 |
| 2025-11-14 | 5,971,436 | +4.5% | 1,874,788 | 3.19 |
| 2025-10-31 | 5,711,586 | +8.9% | 1,237,627 | 4.61 |
| 2025-10-15 | 5,242,339 | -8.8% | 2,036,264 | 2.57 |
| 2025-09-30 | 5,745,021 | -2.4% | 1,566,459 | 3.67 |
| 2025-09-15 | 5,886,314 | -1.3% | 1,480,004 | 3.98 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 17 September 2026, the short share of NVCR volume is 47.6%, down 29.9 points over the last five sessions. Over the last 52 readings it ranged from 18.0% (19 August 2026) to 82.7% (8 September 2026). The latest reading is 12.5 points below the 30-session average of 60.1%, on 464K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-17 | 221K | 464K | 47.6% | 2 |
| 2026-09-16 | 240K | 356K | 67.3% | 1 |
| 2026-09-15 | 192K | 278K | 69.0% | 108 |
| 2026-09-14 | 260K | 351K | 74.1% | 72 |
| 2026-09-11 | 250K | 358K | 69.9% | 133 |
| 2026-09-10 | 493K | 636K | 77.5% | 116 |
| 2026-09-09 | 280K | 379K | 73.9% | 0 |
| 2026-09-08 | 475K | 574K | 82.7% | 70 |
| 2026-09-04 | 127K | 225K | 56.4% | 98 |
| 2026-09-03 | 172K | 246K | 69.9% | 1,342 |
| 2026-09-02 | 222K | 349K | 63.7% | 46 |
| 2026-09-01 | 174K | 297K | 58.6% | 512 |
| 2026-08-31 | 173K | 277K | 62.4% | 0 |
| 2026-08-28 | 145K | 220K | 65.9% | 2,500 |
| 2026-08-27 | 132K | 231K | 57.1% | 0 |
| 2026-08-26 | 183K | 268K | 68.3% | 0 |
| 2026-08-25 | 208K | 326K | 63.8% | 1,215 |
| 2026-08-24 | 163K | 251K | 65.0% | 53 |
| 2026-08-21 | 166K | 292K | 56.8% | 0 |
| 2026-08-20 | 197K | 418K | 47.3% | 1,005 |
| 2026-08-19 | 290K | 1.6M | 18.0% | 692 |
| 2026-08-18 | 168K | 288K | 58.3% | 55 |
| 2026-08-17 | 180K | 332K | 54.2% | 58 |
| 2026-08-14 | 185K | 250K | 74.1% | 172 |
| 2026-08-13 | 115K | 216K | 53.3% | 284 |
| 2026-08-12 | 83K | 245K | 33.9% | 5 |
| 2026-08-11 | 173K | 342K | 50.5% | 5,056 |
| 2026-08-10 | 147K | 362K | 40.7% | 10 |
| 2026-08-07 | 164K | 309K | 53.1% | 100 |
| 2026-08-06 | 234K | 331K | 70.9% | 60 |
Fails to deliver
SEC, by settlement date. JSONAs of 31 August 2026, the fails-to-deliver balance in NVCR is 1,422 shares, down 20,860 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (18 August 2025) to 52,177 shares (4 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-31 | 1,422 | $17.82 | $25K |
| 2026-08-27 | 22,282 | $17.89 | $399K |
| 2026-08-24 | 1,376 | $17.10 | $24K |
| 2026-08-11 | 366 | $17.31 | $6K |
| 2026-08-04 | 52,177 | $15.32 | $799K |
| 2026-07-16 | 279 | $16.03 | $4K |
| 2026-07-15 | 443 | $15.55 | $7K |
| 2026-06-15 | 161 | $17.78 | $3K |
| 2026-06-10 | 2 | $17.24 | $34 |
| 2026-05-26 | 29,728 | $17.96 | $534K |
| 2026-05-18 | 950 | $17.58 | $17K |
| 2026-05-12 | 488 | $18.10 | $9K |
| 2026-05-08 | 468 | $16.83 | $8K |
| 2026-05-04 | 743 | $16.62 | $12K |
| 2026-04-30 | 15 | $11.93 | $179 |
| 2026-04-28 | 473 | $12.48 | $6K |
| 2026-04-27 | 153 | $12.47 | $2K |
| 2026-04-23 | 414 | $13.02 | $5K |
| 2026-04-22 | 484 | $12.23 | $6K |
| 2026-04-21 | 18,366 | $12.67 | $233K |
| 2026-04-20 | 8,133 | $12.83 | $104K |
| 2026-04-17 | 455 | $12.62 | $6K |
| 2026-04-16 | 187 | $12.17 | $2K |
| 2026-04-07 | 108 | $10.55 | $1K |
| 2026-04-06 | 257 | $10.55 | $3K |
| 2026-02-25 | 1,605 | $11.74 | $19K |
| 2026-02-20 | 1,775 | $11.39 | $20K |
| 2026-02-17 | 1,238 | $10.99 | $14K |
| 2026-02-13 | 141 | $12.53 | $2K |
| 2026-02-03 | 518 | $12.19 | $6K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for NVCR in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: Leonard Frank X (Chief Executive Officer) on 2026-06-04.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Leonard Frank X | Chief Executive Officer | Sell | 34K | $17.93 | $615K | 460K |
| 2026-06-03 | Stafford Kristin | n/a | Grant | 12K | $0.00 | $0 | 23K |
| 2026-06-03 | Ocean Allyson J | n/a | Grant | 12K | $0.00 | $0 | 23K |
| 2026-06-03 | Scannell Timothy J | n/a | Grant | 12K | $0.00 | $0 | 26K |
| 2026-06-03 | VERNON W ANTHONY | n/a | Grant | 12K | $0.00 | $0 | 209K |
| 2026-06-03 | Madden Martin J. | n/a | Grant | 12K | $0.00 | $0 | 30K |
| 2026-06-03 | LEUNG GABRIEL | n/a | Grant | 12K | $0.00 | $0 | 101K |
| 2026-06-03 | Hung David | n/a | Grant | 12K | $0.00 | $0 | 32K |
| 2026-06-03 | HILLEMAN JERYL L | n/a | Grant | 12K | $0.00 | $0 | 25K |
| 2026-06-02 | Stafford Kristin | n/a | Sell | 3K | $15.77 | $46K | 11K |
| 2026-06-02 | Ocean Allyson J | n/a | Sell | 3K | $15.77 | $46K | 11K |
| 2026-06-02 | Scannell Timothy J | n/a | Sell | 3K | $15.77 | $46K | 14K |
| 2026-06-02 | VERNON W ANTHONY | n/a | Sell | 3K | $15.77 | $46K | 198K |
| 2026-06-02 | LEUNG GABRIEL | n/a | Sell | 3K | $15.77 | $46K | 89K |
| 2026-06-02 | Hung David | n/a | Sell | 3K | $15.77 | $46K | 20K |
| 2026-06-02 | HILLEMAN JERYL L | n/a | Sell | 3K | $15.77 | $46K | 14K |
| 2026-04-28 | VERNON W ANTHONY | n/a | Option exercise | 22K | $11.39 | $245K | 201K |
| 2026-03-05 | Paravasthu Mukund | Chief Operating Officer | Sell | 43K | $13.77 | $596K | 73K |
| 2026-03-04 | Paravasthu Mukund | Chief Operating Officer | Sell | 5K | $13.31 | $72K | 116K |
| 2026-03-04 | Puri Michal Nath | Chief Human Resources Officer | Sell | 1K | $13.31 | $15K | 201K |
| 2026-03-04 | Weinberg Uri | Chf Medical and Innovation Ofr | Sell | 6K | $13.31 | $85K | 267K |
| 2026-03-04 | Leupin Nicolas | Former Chief Medical Officer | Sell | 1K | $13.31 | $15K | 103K |
| 2026-03-04 | Leonard Frank X | Chief Executive Officer | Sell | 6K | $13.31 | $75K | 494K |
| 2026-03-04 | Cordova Ashley | Former Chief Executive Officer | Tax withholding | 18K | $13.30 | $235K | 423K |
| 2026-03-04 | Brackmann Christoph | Chief Financial Officer | Sell | 6K | $13.31 | $85K | 183K |
| 2026-03-03 | Paravasthu Mukund | Chief Operating Officer | Grant | 45K | $0.00 | $0 | 121K |
| 2026-03-03 | Puri Michal Nath | Chief Human Resources Officer | Grant | 40K | $0.00 | $0 | 202K |
| 2026-03-03 | Weinberg Uri | Chf Medical and Innovation Ofr | Grant | 50K | $0.00 | $0 | 274K |
| 2026-03-03 | Leonard Frank X | Chief Executive Officer | Grant | 150K | $0.00 | $0 | 499K |
| 2026-03-03 | DOYLE WILLIAM F | Executive Chairman | Sell | 21K | $13.43 | $286K | 328K |
| 2026-03-03 | DOYLE WILLIAM F | Executive Chairman | Sell | 51K | $12.79 | $646K | 350K |
| 2026-03-03 | DOYLE WILLIAM F | Executive Chairman | Grant | 200K | $0.00 | $0 | 400K |
| 2026-03-03 | DOYLE WILLIAM F | Executive Chairman | Grant | 200K | $0.00 | $0 | 200K |
| 2026-03-03 | Brackmann Christoph | Chief Financial Officer | Grant | 55K | $0.00 | $0 | 189K |
| 2026-03-03 | Ben Arye Barak | General Counsel | Grant | 50K | $0.00 | $0 | 242K |
| 2026-03-02 | Paravasthu Mukund | Chief Operating Officer | Sell | 408 | $13.49 | $6K | 76K |
| 2026-03-02 | Weinberg Uri | Chf Medical and Innovation Ofr | Sell | 3K | $13.33 | $44K | 223K |
| 2026-03-02 | Leonard Frank X | Chief Executive Officer | Sell | 7K | $13.49 | $98K | 349K |
| 2026-03-02 | Cordova Ashley | Former Chief Executive Officer | Tax withholding | 7K | $13.67 | $99K | 440K |
| 2026-03-02 | Cordova Ashley | Former Chief Executive Officer | Tax withholding | 2K | $13.67 | $33K | 447K |
| 2026-02-28 | Weinberg Uri | Chf Medical and Innovation Ofr | Grant | 13K | $0.00 | $0 | 227K |
| 2026-02-28 | Leonard Frank X | Chief Executive Officer | Grant | 19K | $0.00 | $0 | 357K |
| 2026-02-28 | Cordova Ashley | Former Chief Executive Officer | Grant | 24K | $0.00 | $0 | 450K |
| 2026-02-28 | Ben Arye Barak | General Counsel | Grant | 18K | $0.00 | $0 | 192K |
| 2026-02-27 | Paravasthu Mukund | Chief Operating Officer | Sell | 2K | $13.66 | $21K | 77K |
| 2026-02-27 | Puri Michal Nath | Chief Human Resources Officer | Sell | 1K | $13.66 | $20K | 162K |
| 2026-02-27 | Weinberg Uri | Chf Medical and Innovation Ofr | Sell | 7K | $13.84 | $103K | 214K |
| 2026-02-27 | Leupin Nicolas | Former Chief Medical Officer | Sell | 1K | $13.66 | $14K | 104K |
| 2026-02-27 | Leonard Frank X | Chief Executive Officer | Sell | 10K | $13.66 | $133K | 338K |
| 2026-02-27 | Cordova Ashley | Former Chief Executive Officer | Tax withholding | 12K | $13.75 | $159K | 426K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON12 Form 144 notices on file for NVCR worth $3.4M at the prices reported; 1 in the last 90 days worth $609K. Latest: NICOLAS LEUPIN filed on 2026-07-23 to sell 39,088 shares ($609K) from 2026-07-23.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-23 | NICOLAS LEUPINOfficer | 39K | $609K | 0.034% | 2026-07-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | FRANCIS LEONARDOfficer | 34K | $615K | 0.030% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-05 | MUKUND PARAVASTHUOfficer | 43K | $596K | 0.038% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | URI WEINBERGOfficer | 6K | $85K | 0.006% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | MUKUND PARAVASTHUOfficer | 5K | $72K | 0.005% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | FRANCIS LEONARDOfficer | 6K | $75K | 0.005% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | CHRISTOPH BRACKMANNOfficer | 6K | $85K | 0.006% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | WILLIAM DOYLEOfficer, Director | 72K | $933K | 0.063% | 2026-03-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | URI WEINBERGOfficer | 3K | $44K | 0.003% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | FRANCIS LEONARDOfficer | 7K | $98K | 0.006% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-27 | URI WEINBERGOfficer | 7K | $103K | 0.007% | 2026-02-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-27 | FRANCIS LEONARDOfficer | 10K | $133K | 0.009% | 2026-02-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON9 holders above 5% have filed on NVCR, all on Schedule 13G (passive). The largest reported stake is Guy Levy at 9.1% of the class (10,492,391 shares), filed 2026-05-08 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-08 | 13G/Ano. 4 | Guy Levyindividual | 10.5M | 9.1% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital Management, L.P.partnership | 10.5M | 9.1% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital Master Fund, L.P.non-US institution | 10.5M | 9.1% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus GP, LLCother entity | 10.5M | 9.1% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital Group, LLCother entity | 10.5M | 9.1% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital, LLCother entity | 10.5M | 9.1% | 2026-03-31 |
| 2026-04-28 | 13G | Vanguard Portfolio Managementinvestment adviser | 6.3M | 5.6% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 8 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-12 | 13G/Ano. 3 | Soleus Capital Management, L.P.partnership | 8.5M | 7.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Soleus Capital Master Fund, L.P.non-US institution | 8.5M | 7.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Soleus Capital, LLCother entity | 8.5M | 7.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Soleus Capital Group, LLCother entity | 8.5M | 7.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Soleus GP, LLCother entity | 8.5M | 7.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | Guy Levyindividual | 8.5M | 7.6% | 2025-12-31 |
| 2025-11-13 | 13G/Ano. 1 | Capital World Investorsinvestment adviser | 2.0M | 1.8% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 2 | Guy Levyindividual | 9.6M | 8.6% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 2 | Soleus Capital Master Fund, L.P.non-US institution | 9.6M | 8.6% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 2 | Soleus Capital Management, L.P.partnership | 9.6M | 8.6% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 2 | Soleus Capital Group, LLCother entity | 9.6M | 8.6% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 2 | Soleus Capital, LLCother entity | 9.6M | 8.6% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 2 | Soleus GP, LLCother entity | 9.6M | 8.6% | 2025-09-30 |
13F holders
Tracked managers holding NVCR at their latest 13F. JSON7 of the 30 tracked managers held NVCR at their latest 13F, $84.1M in total at quarter-end prices. Renaissance Technologies is the largest at $29.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 2.0M | $29.6M | 0.04% | +400K |
| AQR Capital Management | 2026-06-30 | 1.1M | $16.7M | 0.01% | +827K |
| D. E. Shaw & Co. | 2026-06-30 | 1.0M | $15.5M | 0.01% | +375K |
| Point72 Asset Management | 2026-06-30 | 803K | $12.2M | 0.01% | -558K |
| Citadel Advisors | 2026-06-30 | 374K | $5.7M | 0.00% | +175K |
| Millennium Management | 2026-06-30 | 278K | $4.2M | 0.00% | +187K |
| Two Sigma Investments | 2026-06-30 | 21K | $321K | 0.00% | -24K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) NovoCure Ltd reported revenue of $183.6M, up 15.6% from the same quarter a year earlier, and net loss of $15.7M (-0.13 diluted EPS). In FY 2024 it generated -$26.4M of operating cash flow.
- Cash
- $93.7M
- Equity
- $338.1M
- Total assets
- $795.2M
- Shares outstanding
- 116,445,840
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $183.6M | -$15.7M | -8.5% | -0.13 |
| Q1 2026 | 2026-03-31 | $174.1M | -$71.1M | -40.9% | -0.62 |
| Q3 2025 | 2025-09-30 | $167.2M | -$37.3M | -22.3% | -0.33 |
| Q2 2025 | 2025-06-30 | $158.8M | -$40.1M | -25.3% | -0.36 |
| Q1 2025 | 2025-03-31 | $155.0M | -$34.3M | -22.1% | -0.31 |
| Q4 2024derived | 2024-12-31 | $161.3M | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $155.1M | -$30.6M | -19.7% | -0.28 |
| Q2 2024 | 2024-06-30 | $150.4M | -$33.4M | -22.2% | -0.31 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2024 | 2024-12-31 | $605.2M | n/a | -$26.4M | $42.9M | n/a | n/a |
| FY 2023 | 2023-12-31 | $509.3M | n/a | -$73.3M | $27.1M | n/a | n/a |
| FY 2022 | 2022-12-31 | $537.8M | n/a | $30.8M | $21.4M | n/a | n/a |
| FY 2021 | 2021-12-31 | $535.0M | n/a | $82.8M | $24.2M | n/a | n/a |
| FY 2020 | 2020-12-31 | $494.4M | $19.8M | $99.1M | $15.0M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-17 from the cover page.
What this page is
NovoCure Ltd in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows NovoCure Ltd (NVCR), SEC CIK 1645113, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-31.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-17.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-31.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-07-23.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-05-08.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K Item 2.02 (full-text search)EDGAR full-text search read twice a day; the estimate is last year's date plus 52 weeks. Latest 2026-07-23.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-06-04.JSON and CSV
- Company record
- EDGAR filing index for CIK 1645113Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 18 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
- BSXBOSTON SCIENTIFIC CORP
- TNDMTANDEM DIABETES CARE INC
- DXCMDEXCOM INC
- PENPenumbra Inc
- SIBNSI-BONE, Inc.
- MMM3M CO
- LMATLEMAITRE VASCULAR INC
- INSPInspire Medical Systems, Inc.
- RMDRESMED INC
- SYKSTRYKER CORP
- GKOSGLAUKOS Corp
- IRTCiRhythm Holdings, Inc.
- ICUIICU MEDICAL INC/DE
- ATECAlphatec Holdings, Inc.
- AORTARTIVION, INC.
- PODDINSULET CORP
- BDXBECTON DICKINSON & CO
- IRMDIRADIMED CORP
- ATRCAtriCure, Inc.
- UFPTUFP TECHNOLOGIES INC
- LUNGPulmonx Corp
- MMSIMERIT MEDICAL SYSTEMS INC
- ANGOANGIODYNAMICS INC
- OFIXOrthofix Medical Inc.
Datasets
Frequently Asked Questions
How much of NVCR is sold short?
What is NVCR's daily short volume?
Does NVCR have fails to deliver?
Are NVCR insiders buying or selling?
Have NVCR insiders filed to sell?
Who owns more than 5% of NVCR?
What did NVCR report last quarter?
Which funds hold NVCR?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.